Want to join the conversation?
$ABBV said Stemcentrx has a broad development program for Rova-T currently underway. The confirmatory third-line trial which is called Trinity began in January and is expected to complete enrollment by the end of 2016 with commercialization expected in 2018. Stemcentrx is also moving into front-line, small cell lung cancer with Rova-T.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?